Trial Profile
A randomized, double-blind, placebo-controlled multicenter study of Secukinumab (AIN457) to examine the clinical efficacy and the NSAID-sparing effect of Secukinumab over 16 weeks in patients with ankylosing spondylitis (ASTRUM)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms ASTRUM
- Sponsors Novartis; Novartis Pharmaceuticals
- 09 Nov 2021 Results evaluating the short-term NSAID sparing effect of secukinumab in Ankylosing Spondylitis Patients with NSAID intake, presented at the ACR Convergence 2021
- 05 Jun 2021 Primary endpoint (Proportion of Patients Who Achieved ASAS20 Response in the Pooled Secukinumab Group Compared With the Placebo Group at Week 12) has not been met as per results presented at the 22nd Annual Congress of the European League Against Rheumatism
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism